RPG Life Sciences plans ₹500 crore for manufacturing expansion
In short
RPG Life Sciences said it will spend ₹500 crore over the next 12 months to build up its factories and API business. The company has already done about ₹200 crore of acquisitions and says it has ₹700 crore of committed capital.
This could help the drug firm grow faster, but the exact companies it may buy and the final deal details are not stated.
What the reporting says
RPG Life Sciences said it plans to deploy ₹500 crore over the next 12 months to strengthen manufacturing and API capabilities through strategic acquisitions. The company’s managing director, Ashok Nair, said the firm has already made acquisitions worth about ₹200 crore and has a committed capital infusion of ₹700 crore. The immediate impact is a larger expansion push, but the exact targets and deals are not stated.
Why it matters
RPG Life Sciences said it will use ₹500 crore in the next 12 months to expand manufacturing and API capacity through acquisitions. Managing director Ashok Nair said the company has already completed about ₹200 crore of purchases and has a committed capital infusion of ₹700 crore. The reporting does not name the assets, sellers, or timing beyond the next 12 months, so the final scope remains unclear.